Continuous morphine infusion for end-stage lung cancer patients

  • Authors:
    • Young Hak Kim
    • Chiyuki Okuda
    • Yuichi Sakamori
    • Katsuhiro Masago
    • Yosuke Togashi
    • Michiaki Mishima
  • View Affiliations

  • Published online on: December 28, 2012     https://doi.org/10.3892/ol.2012.1101
  • Pages: 972-974
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

End-stage cancer patients frequently receive continuous morphine infusion (CMI) to alleviate the various symptoms associated with cancer progression or adverse events; however, there have been a limited number of studies concerning such patients. We conducted a retrospective analysis of 79 end-stage lung cancer patients who received CMI at the Kyoto University Hospital, Kyoto, Japan between 2008 and 2010. Thirty-one patients (39%) received CMI intravenously and 48 (61%) received it subcutaneously. The patients were divided into four groups based on the indications for CMI: group A (uncontrolled pain; n=9), group B (dyspnea; n=44), group C (both dyspnea and pain; n=13) and group D (an inability to take oral medicine; n=13). The median maximum dose of morphine in groups A‑D was 60.0, 25.0, 50.0 and 15.0 mg/day, respectively. The median survival time from the start of CMI was 4 days (range 0-136). In our limited experience, pain, dyspnea and the inability to take oral medicine were identified as indications for CMI in end-stage lung cancer patients, with dyspnea being the major indication for CMI. Patients in group B (dyspnea) required a lower dose of morphine for alleviation compared with those in groups A (uncontrolled pain) and C (both dyspnea and pain). The survival time from the initiation of CMI was markedly shorter in patients with dyspnea (groups B and C) than in patients without dyspnea (group A). Further studies are required to facilitate the effective and appropriate use of CMI in end-stage lung cancer patients. Dyspnea was the major indication for CMI in end-stage lung cancer patients, and the survival time was extensively limited in such patients.
View Figures
View References

Related Articles

Journal Cover

March 2013
Volume 5 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim YH, Okuda C, Sakamori Y, Masago K, Togashi Y and Mishima M: Continuous morphine infusion for end-stage lung cancer patients. Oncol Lett 5: 972-974, 2013
APA
Kim, Y.H., Okuda, C., Sakamori, Y., Masago, K., Togashi, Y., & Mishima, M. (2013). Continuous morphine infusion for end-stage lung cancer patients. Oncology Letters, 5, 972-974. https://doi.org/10.3892/ol.2012.1101
MLA
Kim, Y. H., Okuda, C., Sakamori, Y., Masago, K., Togashi, Y., Mishima, M."Continuous morphine infusion for end-stage lung cancer patients". Oncology Letters 5.3 (2013): 972-974.
Chicago
Kim, Y. H., Okuda, C., Sakamori, Y., Masago, K., Togashi, Y., Mishima, M."Continuous morphine infusion for end-stage lung cancer patients". Oncology Letters 5, no. 3 (2013): 972-974. https://doi.org/10.3892/ol.2012.1101